XOMA Royalty Corp Dossier - Source-backed chat

XOMA Royalty Corp

XOMANASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.91

Intrinsic Value $14.39median of 3 methodsbased on filings through 31 Mar 2026

Market Price $40.17Price as of 13 Jul 2026

Significantly overvaluedIntrinsic value is 64% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-64%)

Data confidence Sign in to view data confidence

Market Cap $710.2M

Enterprise Value $727.4M

Shares Outstanding 17.6M diluted

Moat Rating None

Last ex-dividend3 Jan 2025

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

XOMA Royalty Corp is in the process of being acquired by Ligand Pharmaceuticals Incorporated under a definitive merger agreement announced on April 27, 2026. Under the terms of the agreement, Ligand will acquire all outstanding common shares of XOMA for $39.00 per share in cash, representing a total equity value of approximately $739 million. In addition to the cash consideration, XOMA stockholders will receive one non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of the net proceeds from XOMA's ongoing litigation with Janssen Biotech regarding Tremfya royalties. Because the stock is trading near the cash acquisition price of $39.00 (currently around $41.70 to $42.00, reflecting the option value of the CVR), the investment thesis has shifted from a standalone growth story to a merger arbitrage and CVR optionality play. A 'Hold' recommendation is appropriate as the downside is protected by the $39.00 cash floor, while the CVR provides potential upside from the Janssen litigation.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$39.00

Mean target$39.00

High · most bullish analyst$39.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The merger agreement is terminated due to regulatory hurdles, failure to obtain majority stockholder approval, or other closing condition failures. XOMA must pay a $40 million termination fee if it accepts a superior proposal. Standalone, the stock drops back to its pre-announcement trading range near $34.00-$36.00, and the Janssen litigation results in an unfavorable ruling, rendering the CVR worthless.

Base CaseCentral scenario

The merger with Ligand Pharmaceuticals closes successfully in the third quarter of 2026. XOMA stockholders receive $39.00 per share in cash, and the Series A and Series B preferred shares are fully redeemed. Stockholders receive their non-transferable CVRs, and the Janssen litigation continues under the CVR Trust structure, eventually yielding moderate payouts.

Bull CaseUpside scenario

XOMA's business model as a royalty aggregator offers a predictable and defensive revenue stream compared to traditional biotech companies, mitigating single-asset risk by diversifying across multiple therapeutic indications and development stages. The portfolio features high-potential commercial and late-stage clinical assets, including Vabysmo, Ojemda, and Miplyffa, which provide significant cash flow and milestone potential.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Guaranteed cash floor of $39.00 per share from the pending Ligand acquisition.
Significant upside potential from the non-transferable CVR representing 75% of net proceeds from the Janssen Biotech Tremfya litigation.
Strong voting support with approximately 47% of common stock on an as-converted basis committed to vote in favor of the transaction.

Key Investment Risks

Transaction failure risk if regulatory approvals (HSR) or stockholder approvals are not obtained.
Opportunity cost of capital as the stock is likely to remain range-bound near the acquisition price until closing.
Litigation risk where the Janssen Biotech dispute could result in zero recovery, making the CVR worthless.

Thesis Invalidation Triggers

Termination of the merger agreement by either Ligand or XOMA.
A material adverse ruling in the Janssen Biotech Tremfya litigation prior to the merger close.
Failure of XOMA stockholders to approve the merger at the upcoming special meeting.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.